List of works - Marit J. van Gils

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies

scientific article

Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets

scientific article

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

scientific article published on 23 December 2020

Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19

scientific article published on 19 May 2020

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

scientific article published on 29 September 2020

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability

scientific article

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

scientific article published on 27 July 2020

Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses

scientific article

Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes

scientific article published on 30 September 2019

Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits

scientific article published on 17 March 2020

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface

scientific article

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

scientific article published on 24 April 2014

Broadly neutralizing antibodies against HIV-1: templates for a vaccine

scientific article published on January 2013

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection

scientific article published on 17 June 2009

Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes

article

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

scientific article

Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

scientific article published on 24 September 2020

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies

scientific article published on 01 June 2019

Correction: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

scientific article

Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?

scientific article published on December 2010

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

scientific article

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity

scientific article published on 03 August 2020

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

article

Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains

scientific article published on 08 June 2020

Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer

scientific article

Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice

scientific article published on 01 January 2020

Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

scientific article

Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers

scientific article published in May 2014

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure

scientific article

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

scientific article published on 19 September 2019

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

scientific article

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

Ephrin-Eph signaling usage by a variety of viruses

scientific article published on 18 June 2020

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

scientific article published on 23 February 2018

Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum

scientific article

From affinity selection to kinetic selection in Germinal Centre modelling

scientific article published on 03 June 2022

Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection

scientific article published on 17 July 2010

Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals

scientific article

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite

scientific article published on 05 June 2020

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

scientific article

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients.

scientific article published on 3 October 2011

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans

scientific article

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.

scientific article published on 23 September 2013

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds

scientific article published on 07 July 2016

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth

article

High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz

scientific article

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

scientific article

Hitting HIV's Harpoon

article

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies

scientific article published on 17 August 2016

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

scientific article

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization

scientific article

In vivo protection by broadly neutralizing HIV antibodies

scientific article

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

scientific article published on 12 August 2015

Infection and transmission of SARS-CoV-2 depends on heparan sulfate proteoglycans

scientific article

Infection and transmission of SARS‐CoV‐2 depends on heparan sulfate proteoglycans

scientific article

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies

scientific article

Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity

scientific article published on 7 December 2011

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. ⬇️

scientific article published on 25 April 2019

Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates

scientific article published on 31 August 2020

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity

scientific article

Natural infection as a blueprint for rational HIV vaccine design

scientific article published on 20 September 2016

Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions

scientific article published on 12 May 2020

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation

scientific article published on 29 December 2020

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizers

scientific article published on 30 September 2020

Opposites attract in bispecific antibody engineering

scientific article

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

scientific article published on 13 May 2020

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

scientific article published on 15 June 2020

Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu

scientific article

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

scientific article published in November 2009

Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies

scientific article published on June 2016

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors

scientific article

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

scientific article published on 26 July 2010

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

scientific article published on 12 April 2011

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

scientific article

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

scientific article published on 30 January 2020

SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity

scientific article

SARS-CoV-2 evolution during treatment of chronic infection

Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.

scientific article

Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice

scientific article published on 22 August 2018

Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics

scientific article published on 15 July 2019

Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers

scientific article published on 8 December 2017

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

scientific article

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers

scientific article

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

scientific article published on 29 May 2019

The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype

scientific article

The identification and function of a Netrin-1 mutation in a pedigree with premature atherosclerosis

scientific article published on 28 February 2020

The potential of engineered antibodies for HIV-1 therapy and cure

scientific article published on 15 August 2019

Visualization of the HIV-1 Env Glycan Shield Across Scales

scientific article published on 12 November 2019

Visualization of the HIV-1 Env glycan shield across scales

scientific article published on 22 October 2020

[HIV vaccine: how far along are we?]

scientific article published on 03 September 2020

List of works by Marit J. van Gils

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies

Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses

Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes

Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Broadly neutralizing antibodies against HIV-1: templates for a vaccine

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection

Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller

Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies

Correction: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains

Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer

Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice

Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

Ephrin-Eph signaling usage by a variety of viruses

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum

From affinity selection to kinetic selection in Germinal Centre modelling

Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection

Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth

High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Hitting HIV's Harpoon

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization

In vivo protection by broadly neutralizing HIV antibodies

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

Infection and transmission of SARS-CoV-2 depends on heparan sulfate proteoglycans

Infection and transmission of SARS‐CoV‐2 depends on heparan sulfate proteoglycans

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies

Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. ⬇️

Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity

Natural infection as a blueprint for rational HIV vaccine design

Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizers

Opposites attract in bispecific antibody engineering

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity